DeCure for X-linked hypohidrotic ectodermal dysplasia
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for X-linked hypohidrotic ectodermal dysplasia — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleX-linked hypohidrotic ectodermal dysplasia maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for x-linked hypohidrotic ectodermal dysplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ectodysplasin A (EDA) — EDA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1RJ8 · 2.23 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by mutations in the ED1 gene, also called EDA. A study of 45 Italian males with ED1 mutations found that, beyond the major ectodermal tissues, most patients also had alterations of several minor ectodermal-derived structures. A separate report described a family with XLHED presenting various skin, hair and oral abnormalities. In a Chinese family, a novel missense mutation (c.878T>G) in EDA was detected in two patients and three female carriers, but not in four unaffected family members nor in 120 healthy controls. That mutation had not been reported previously.
The characterisation of the molecular events underlying ectodermal dysplasias has opened the door to gene or protein therapy, but a 2009 perspective article notes both successes and failures of these new treatments. The article argues that a new classification of ectodermal dysplasias based on molecular knowledge is needed to assess the feasibility of such therapies. No clinical trial results for any drug or biologic in XLHED patients are reported in these abstracts.
What is still missing is any published evidence from controlled human trials of a specific therapy. The abstracts provide no data on survival, response rates, or sample sizes for any intervention. The field lacks a completed trial of a protein replacement or gene therapy that reports efficacy or safety outcomes in patients.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 2014 · 20 citations
Phenotypic heterogeneity and mutational spectrum in a cohort of 45 Italian males subjects with X‐linked ectodermal dysplasia
AbstractEctodermal dysplasias (EDs) are a group of genetic disorders characterized by the abnormal development of the ectodermal-derived structures. X-linked hypohidrotic ectodermal dysplasia, resulting from mutations in ED1 gene, is the most common form. The main purpose of this study was to characterize the phenotype spectrum in 45 males harboring ED1 mutations. The study showed that in addition to the involvement of the major ectodermal tissues, the majority of patients also have alterations of several minor ectodermal-derived structures. Characterizing the clinical spectrum resulting from ED1 gene mutations improves diagnosis and can direct clinical care.
BMJ Case Reports · 2013 · 5 citations · open access
Familial ectodermal dysplasia: a peers' agony
AbstractEctodermal dysplasias include a various group of inherited disorders which share primary defect in the development of two or more tissues of embryonic ectodermal origin. Though there are many subtypes, ectodermal dysplasias are mainly hidrotic ectodermal dysplasia and hypohidrotic ectodermal dysplasia, among which the most common variety is X linked hypohidrotic ectodermal dysplasia. We report a rare case of X linked hypohidrotic ectodermal dysplasia occurring in a family with various skin, hair and oral abnormalities.
American Journal of Medical Genetics Part A · 2009 · 3 citations · open access
Gene therapy and protein therapy of ectodermal dysplasias: A perspective
AbstractEctodermal dysplasias (EDs) form a complex and heterogeneous group of diseases currently defined and classified according to their clinical symptoms. The characterization, for several EDs, of the molecular events underlying their development, not only challenges this classification but also opens the door to new therapeutic options such as gene or protein therapy. This article provides a concise overview of the most recent successes and failures of this new type of treatment and sets in perspective how the specificities of given EDs will influence their feasibility in the near future. It makes the case for the need of new classification of EDs that is based on our most recent knowledge of the molecular basis of these diseases.
Genetics and Molecular Research · 2015 · 3 citations · open access
Identification of a novel mutation of the EDA gene in X-linked hypohidrotic ectodermal dysplasia
AbstractThis study aimed to identify the disease-causing mutation in the ectodysplasin A (EDA) gene in a Chinese family affected by X-linked hypohidrotic ectodermal dysplasia (XLHED). A family clinically diagnosed with XLHED was investigated. For mutation analysis, the coding region of EDA of 2 patients and 7 unaffected members of the family was sequenced. The detected mutation in EDA was investigated in 120 normal controls. A missense mutation (c.878T>G) in EDA was detected in 2 patients and 3 female carriers, but not in 4 unaffected members of the family. The mutation was not found in the 120 healthy controls and has not been reported previously. Our findings indicate that a novel mutation (c.878T>G) of EDA is associated with XLHED and adds to the repertoire of EDA mutations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
